Eloxx Pharmaceuticals, Inc. (ELOX) · Oct 21, 2026 · Other events
Phase 2 ADPKD design — Topline data expected H1 2029 vs prior mid-2028 plan
Eloxx’s new ADPKD clinical trial design adds clarity, but its expected data readout now moves into 2029 and extends the wait.
Eloxx is a clinical-stage biotech focused on exaluren for genetically defined rare kidney diseases: its nearer-term program is the Phase 2b EXACT study in nonsense-mutation Alport syndrome, while ADPKD remains an earlier-stage expansion program.
The ADPKD program is now more concrete, but not closer to a value-inflection point. Eloxx finalized EXPRESS as a roughly 60-patient, randomized Phase 2 trial using 52-week kidney-volume change as the primary endpoint. 〔0〕 (Item 8.01) That is useful design clarity, but it is still a small, early-stage study rather than efficacy evidence.
The important change is the slower timeline. Earlier company planning called for ADPKD topline data by mid-2028, while this filing now points to the first half of 2029; first dosing is not expected until the third quarter of 2027. 〔1〕 (Item 8.01) The delay is partly offset by a finalized protocol and the appointment of a new chief medical officer, but the filing does not add clinical data or reduce development risk.
The board appointment is supportive rather than transformative. Geno Germano brings substantial pharmaceutical development and commercialization experience, and the board expanded from five to six directors. 〔2〕 (Item 5.02) The accompanying option grant is ordinary director compensation, not financing or a material ownership shift.
Bottom line: This filing improves visibility into how Eloxx plans to test exaluren in ADPKD, but the expected readout has moved later, making the net change modestly worse for the near-term development timeline. The more immediate business test remains the Alport program, not this newly specified trial. citeturn0search5
First ADPKD patient dosing, Q3 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!